secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2025-06-09T23:59:59+00:00
Accession:  0000950170-25-083799
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics shareholders elect new director, approve board size increase at 2025 AGM
--------------------------------------------------------------------------------

- New director Briggs W. Morrison, M.D. elected; board size maximum increased.
- Binding votes on executive compensation approved with significant against votes (e.g., equity grant for execs: 31.8M for, 9.0M against).
- Non-binding advisory vote on named executive officer compensation passed with 29.1M for vs 11.7M against.
- Shareholders approved amendments to articles of association, effective June 6, 2025, subject to Swiss registration.
- All director nominees re-elected; auditors Ernst & Young re-elected for FY2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017025083799/0000950170-25-083799-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017025083799/crsp-20250605.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-083799

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer